Skip to main content


  • Commentary
  • Open Access

Epidemiological and clinical aspects of autoimmune thyroid diseases in children with Down’s syndrome

  • 1,
  • 1,
  • 1,
  • 1Email author,
  • 1 and
  • 1
Italian Journal of Pediatrics201844:39

  • Received: 21 December 2017
  • Accepted: 12 March 2018
  • Published:


Aim of this commentary is to report the main peculiarities that have been found to characterize the phenotypic expression of autoimmune thyroid diseases (AITDs) in children with Down’s syndrome (DS). According to recent reports, DS children are, per se, more exposed to the risk of both Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), irrespective of other concomitant risk factors, such as female gender and family antecedents for AITDs. In the context of extra-thyroidal autoimmune disorders, the ones that preferentially aggregate with AITDs in DS children are alopecia areata and vitiligo. Another peculiar aspect, in DS children, is that HT presents with a more severe biochemical picture, which furtherly deteriorates over time. By contrast, GD does not demonstrate a more severe clinical and biochemical picture with respect to that generally observed in patients without DS. Finally, DS children might be at higher risk of progressing from HT toward GD over time.


  • Extra-thyroidal autoimmunity
  • Graves’ disease
  • Hashimoto’s thyroiditis
  • Metamorphic autoimmunity
  • Thyroid status


With a prevalence of 1:800 live births [1], Down’s syndrome (DS) is the commonest chromosomopathy in humans and the most frequent cause of severe learning disabilities [2].

One of the most typical clinical features of DS children is their susceptibility toward several autoimmune diseases, such as Hashimoto’s thyroiditis (HT), Graves’ disease (GD), type 1 diabetes, celiac disease, alopecia, vitiligo and idiopathic arthritis [2, 3]. Furthermore, the association with DS seems to be able to condition, per se, an over-expression of autoimmune phenomena [3], as suggested by both the non-exceptional co-occurrence of many autoimmune disorders [46] and the spontaneous progression from HT to GD, that has been reported to occur more frequently in children with this syndrome [7, 8] than in the pediatric general population [9]. These findings as a whole provide insights into a very aggressive phenotypic expression of autoimmunity in DS children [3, 10].

Another peculiar aspect of autoimmunity in DS children is that the association with this syndrome could modify the clustering of extra-thyroidal autoimmune disorders [3].

Aim of this commentary is to report the current views about the phenotypic peculiarities of DS-related autoimmune thyroid disorders (AITDs), in terms of epidemiology and pathophysiology, presentation, clinical and biochemical course and long-term metamorphic evolution.

Epidemiology and pathophysiology

In DS children, HT is, by far, the most common autoimmune disease ad its prevalence has been reported to be much more elevated than that generally reported in age-matched patients without this chromosomopathy: respectively 13–34% [11, 12] vs 1.3% [13].

In DS children, also the prevalence of GD is known to be higher than in the pediatric general population: respectively 6.5‰ [14] vs 1.07‰ [15].

In patients with this syndrome both HT and GD do not show any gender predominance [8, 16], whilst in individuals without DS they are frequently associated with female sex. Furthermore, the frequency of AITD family antecedents in the history of DS children with either HT [8] or GD [16] is very low, which is atypical and surprising. Both these findings suggest that children with DS are, per se, more prone to the risk of developing AITDs, irrespective of other concomitants risk factors [8, 16, 17].

Another peculiar aspect of AITDs in DS children is that both HT and GD present at a younger age than in the pediatric general population [8, 11, 14, 16, 17]. This finding might be explained by the fact that several pediatricians are aware that DS children are more exposed to the risk of developing concomitant thyroid disorders and, therefore, the observation of a thyroid enlargement or dysfunction in a DS child is probably regarded with greater attention [8].

According to the results of a recent study, the prevalence rate of extra-thyroidal autoimmune disorders in DS children seems to be distinctly higher than in a control population of children without DS [3]. These findings confirm the non-casual association between DS and various extra-thyroidal autoimmune disorders, which had been previously postulated also by other authors [1820]. In the study by Aversa et al. [3], the epidemiological distribution of extra-thyroidal autoimmune diseases was significantly different in two patient cohorts with or without DS. In particular, the prevalence rates of alopecia areata ad vitiligo were significantly more elevated in DS patients, whilst the prevalence of type 1 diabetes did not differ in the two groups and that of celiac disease became significantly more frequent only in the older patients of DS series [3]. The results of such study suggest that AITDs in DS children aged between 1 and 18 years demonstrate a preferential clustering with alopecia areata and vitiligo, irrespective of age [3].

In DS patients it is the organ-specific autoimmunity to be especially enhanced, whereas generalized autoimmunity is not remarkably represented [21]. Therefore, the relationships between DS and autoimmunity might be interpreted on the basis of a functional impairment of T cells, due to insufficient intrathymic expression of the AIRE gene [22], that is located on chromosome 21 and plays an important role in maintaining a balance between autoreactivity and immunoregulations in human autoimmunity [23]. According to this hypothesis, the thymus of children with DS might contain lower levels of the AIRE gene, which can account for both the altered expression of autoimmune regulation and the peculiar autoimmune phenotype of DS patients [3, 24].

AITD presentation

Thyroid function patterns at HT presentation in children and adolescents without DS are known to range from overt hypothyroidism to overt hyperthyroidism [25]. The biochemical picture that is detected most often, at HT diagnosis, is euthyroidism, followed by either overt or subclinical hypothyroidism (SH) or, occasionally, overt and subclinical hyperthyroidism [26].

By contrast, in DS children the most common biochemical pattern, at HT presentation, is by far SH, followed by overt hypothyroidism, euthyroidism and hyperthyroidism, in decreasing order [17]. The prevalence of euthyroidism, at HT diagnosis, is significantly lower in DS children than in those without DS (Fig. 1).
Fig. 1
Fig. 1

Prevalence rates (%) of the biochemical pictures of thyroid function found, at diagnosis of Hashimoto’s thyroiditis (HT), in two cohorts of HT children with (Group A) or without Down’s syndrome (Group B) (according to the results of Reference [8] study)

The more severe biochemical presentation of HT in DS children might be interpreted on the light of a congenital alteration in thyroid gland regulation, that is peculiar of the individuals with this syndrome, irrespective of autoimmunity [27].

By contrast, the clinical presentation of GD in DS children does not seem to differ from that observed in children without DS [14, 16]. In fact, at GD presentation, the prevalence rates of both exophthalmos and other hyperthyroid manifestations were found to be very similar in DS children and controls [14, 16]. Furthermore, mean FT4 and median TSH receptor autoantibody (TRAB) serum levels did not differ in the two groups and the initial methimazole dosage that was needed in DS patients at the start of therapy, was not different from the one employed in GD children without DS [16].

All these findings as a whole are consistent with the view that GD in DS children does not present with a more severe clinical and biochemical picture.

AITD course

The natural evolution of thyroid status in 146 DS children with HT has been recently investigated throughout a 5-year follow-up [8]. According to the results of that longitudinal study, natural history of thyroid function in DS children with HT seems to be characterized by a progressive deterioration over time, as suggested by the significant decrease in the prevalence rate of euthyroidism from HT diagnosis onward (Fig. 2). As an obvious consequence of such a decrease, almost the totality of DS patients exhibited, 5 years after HT presentation, a hormonal pattern compatible with thyroid dysfunctions: either SH or overt hypothyroidism or overt hyperthyroidism (Fig. 2). A deterioration of thyroid function over time was also observed in another longitudinal study in DS children with HT-related SH [28]. Therefore, on the light of the results of these longitudinal studies [8, 28], it may be inferred that a prolonged follow-up of thyroid status is necessary in all the DS patients with HT, even in those presenting with euthyroidism and not only in those presenting with SH.
Fig. 2
Fig. 2

Prevalence rates (%) of the biochemical pictures of thyroid function found, both at diagnosis of Hashimoto’s thyroiditis (HT) and 5 years later, in a cohort of 146 children with Down’s syndrome (according to the results of Reference [8] study)

In the study by De Luca et al. [16] on the peculiarities of GD in young patients with DS, the most striking differences between DS children and those without DS concerned clinical response to pharmacological treatment. In fact, DS patients exhibited both lower relapse rates during the first methimazole cycle and higher remission rates after definitive methimazole withdrawal [16]. Furthermore, the methimazole dosages which were needed to maintain euthyroidism under treatment were lower in DS group [16]. It may be argued, on the light of these findings, that clinical course of GD is less severe in children with DS than in those without DS [16]. Such inference is reinforced by the observation that alternative non-pharmacological therapies were never requested in any DS children [16].

To sum up, whilst the course of HT in the children with DS has been repeatedly reported to be more severe that in age-matched individuals [8, 28], the course of DS-related GD seems to be relatively mild [16]. Therefore, it may be inferred that the association with DS might have a dichotomic impact on the phenotypic expression of these autoimmune disorders.

Long-term metamorphic evolution

The metamorphosis of clinical phenotype from HT to GD or vice versa has been, during the last 10 years, the theme of many reports, which concluded that there exists a continuum between these disorders within the spectrum of AITDs [29, 30].

However, whereas the progression from HT to GD in the pediatric general population involves only 3.7% of children [9], this metamorphosis seems to be by far more frequent in the children with DS: 25% of cases [31]. On the light of these findings, it was suggested that DS children with concomitant HT might be at higher risk of progressing toward GD [7, 8, 17, 31], although the pathophysiological bases of such a predisposition were not elucidated [32].


1) DS children are, per se, more exposed to the risk of AITDs, irrespective of other concomitant risk factors; 2) the extra-thyroidal autoimmune disorders which cluster most frequently with AITDs in DS children are alopecia areata and vitiligo; 3) in DS children, HT presents with a more severe biochemical picture, that furtherly deteriorates over time; 4) by contrast, GD presentation and course are not more severe in DS children than in those without DS.



Autoimmune thyroid disorders


Down syndrome


Graves’ disease


Hashimoto’s thyroiditis


Subclinical hypothyroidism


TSH receptor autoantibodies



Not applicable.


This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Availability of data and materials

Not applicable.

Authors’ contributions

TA and MV have organized the material and prepared its distribution in the different sections; GC and RG have written the paper; GZ has prepared the graphics; FDL has collected references. Each Author listed on the manuscript has seen and approved the submission of the present version of the manuscript and takes full responsibility for the manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Human Pathology in Adulthood and Childhood, University of Messina, Via Consolare Valeria, 98124 Messina, Italy


  1. Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. 2006;76:747–56.View ArticlePubMedGoogle Scholar
  2. Iughetti L, Lucaccioni L, Fugetto F, Mason A, Predieri B. Thyroid function in down syndrome. Expert Rev Endocrinol Metab. 2015;10:525–32.View ArticleGoogle Scholar
  3. Aversa T, Valenzise M, Corrias A, Salerno M, Iughetti L, Tessaris D, et al. In children with autoimmune thyroid diseases the association with down syndrome can modify the clustering of extra-thyroidal autoimmune disorders. J Pediatr Endocrinol Metab. 2016;29:1041–6.View ArticlePubMedGoogle Scholar
  4. Kinik ST, Ozçay F, Varan B. Type I diabetes mellitus, Hashimoto's thyroiditis and celiac disease in an adolescent with down syndrome. Pediatr Int. 2006;48:433–5.View ArticlePubMedGoogle Scholar
  5. Lämmer C, Weimann E. Early onset of type I diabetes mellitus, Hashimoto's thyroiditis and celiac disease in a 7-yr-old boy with Down's syndrome. Pediatr Diabetes. 2008;9:423–5.View ArticlePubMedGoogle Scholar
  6. Salzano G, Lombardo F, Arrigo T, Sferlazzas C, Wasniewska M, Valenzise M, et al. Association of five autoimmune diseases in a young woman with Down's syndrome. J Endocrinol Investig. 2010;33:202–3.View ArticleGoogle Scholar
  7. Aversa T, Lombardo F, Corrias A, Salerno M, De Luca F, Wasniewska M. In young patients with turner or down syndrome, Graves’ disease presentation is often preceded by Hashimoto's thyroiditis. Thyroid. 2014;24:744–7.View ArticlePubMedGoogle Scholar
  8. Aversa T, Salerno M, Radetti G, Faienza MF, Iughetti L, Corrias A, et al. Peculiarities of presentation and evolution over time of Hashimoto's thyroiditis in children and adolescents with Down's syndrome. Hormones. 2015;14:410–6.PubMedGoogle Scholar
  9. Wasniewska M, Corrias A, Arrigo T, Lombardo F, Salerno M, Mussa A, et al. Frequency of Hashimoto’s thyroiditis antecedents in the history of children and adolescents with graves’ disease. Horm Res Paediatr. 2010;73:473–6.View ArticlePubMedGoogle Scholar
  10. Aitken RJ, Mehers KL, Williams AJ, Brown J, Bingley PJ, Holl RW, et al. Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in down syndrome. Diabetes Care. 2013;36:1181–5.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Popova G, Paterson WF, Brown A, Donaldson MD. Hashimoto's thyroiditis in Down's syndrome: clinical presentation and evolution. Horm Res. 2008;70:278–84.View ArticlePubMedGoogle Scholar
  12. Jørgensen KT, Rostgaard K, Bache I, Biggar RJ, Nielsen NM, Tommerup N, Frisch M. Autoimmune diseases in women with Turner's syndrome. Arthritis Rheum. 2010;62:658–66.View ArticlePubMedGoogle Scholar
  13. Tozzoli R, Perini R. Malattie autoimmuni nei primi anni di vita: dai sintomi alla diagnosi di laboratorio. La Rivista Italiana della Medicina di Laboratorio. 2007;3:45–50.Google Scholar
  14. Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, Chillaron-Jordan JJ, Corretger JM, Cano-Pérez JF. Hyperthyroidism in a population with down syndrome (DS). Clin Endocrinol. 2009;71:110–4.View ArticleGoogle Scholar
  15. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2:119–25.View ArticlePubMedGoogle Scholar
  16. De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, Cassio A, et al. Peculiarities of graves’ disease in children and adolescents with Down’s syndrome. Eur J Endocrinol. 2010;162:591–5.View ArticlePubMedGoogle Scholar
  17. Aversa T, Lombardo F, Valenzise M, Messina MF, Sferlazzas C, Salzano G, et al. Peculiarities of autoimmune thyroid diseases in children with turner or down syndrome: an overview. Ital J Pediatr. 2015;41:39.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Carnicer J, Farré C, Varea V, Vilar P, Moreno J, Artigas J. Prevalence of coeliac disease in Down's syndrome. Eur J Gastroenterol Hepatol. 2001;13:263–7.View ArticlePubMedGoogle Scholar
  19. Graber E, Chacko E, Regelmann MO, Costin G, Rapaport R. Down syndrome and thyroid function. Endocrinol Metab Clin N Am. 2012;41:735–45.View ArticleGoogle Scholar
  20. King K, O'Gorman C, Gallagher S. Thyroid dysfunction in children with down syndrome: a literature review. Ir J Med Sci. 2014;183:1–6.View ArticlePubMedGoogle Scholar
  21. Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361:1281–9.View ArticlePubMedGoogle Scholar
  22. Giménez-Barcons M, Casteràs A, Armengol Mdel P, Porta E, Correa PA, Marín A, et al. Autoimmune predisposition in down syndrome may result from a partial central tolerance failure due to insufficient intrathymic expression of AIRE and peripheral antigens. J Immunol. 2014;193:3872–9.View ArticlePubMedGoogle Scholar
  23. Valenzise M, Meloni A, Betterle C, Giometto B, Autunno M, Mazzeo A, et al. Chronic inflammatory demyelinating polyneuropathy as a possible novel component of autoimmune poly-endocrine-candidiasis-ectodermal dystrophy. Eur J Pediatr. 2009;168:237–40.View ArticlePubMedGoogle Scholar
  24. Skogberg G, Lundberg V, Lindgren S, Gudmundsdottir J, Sandström K, Kämpe O, et al. Altered expression of autoimmune regulator in infant down syndrome thymus, a possible contributor to an autoimmune phenotype. J Immunol. 2014;193:2187–95.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Wasniewska M, Corrias A, Salerno M, Lombardo F, Aversa T, Mussa A, et al. Outcomes of children with hashitoxicosis. Horm Res Paediatr. 2012;77:36–40.View ArticlePubMedGoogle Scholar
  26. De Luca F, Santucci S, Corica D, Pitrolo E, Romeo M, Aversa T. Hashimoto's thyroiditis in childhood: presentation modes and evolution over time. Ital J Pediatr. 2013;39:8.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Claret C, Goday A, Benaiges D, Chillarón JJ, Flores JA, Hernandez E, et al. Subclinical hypothyroidism in the first years of life in patients with down syndrome. Pediatr Res. 2013;73:674–8.View ArticlePubMedGoogle Scholar
  28. Wasniewska M, Aversa T, Salerno M, Corrias A, Messina MF, Mussa A, et al. Five-year prospective evaluation of thyroid function in girls with subclinical mild hypothyroidism of different etiology. Eur J Endocrinol. 2015;173:801–8.View ArticlePubMedGoogle Scholar
  29. Ludgate M, Emerson CH. Metamorphic thyroid autoimmunity. Thyroid. 2008;18:1035–7.View ArticlePubMedGoogle Scholar
  30. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid. 2013;23:14–24.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Aversa T, Valenzise M, Salerno M, Corrias A, Iughetti L, Radetti G, et al. Metamorphic thyroid autoimmunity in down syndrome: from Hashimoto’s thyroiditis to Graves’ disease and beyond. Ital J Pediatr. 2015;41:87.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Valenzise M, Aversa T, Zirilli G, Salzano G, Corica D, Santucci S, De Luca F. Analysis of the factors affecting the evolution over time of subclinical hypothyroidism in children. Ital J Pediatr. 2017;43:2.View ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2018